OBJECTIVES: Approximately a third of patients with Psoriasis are developing Psoriatic arthritis (PsA). This study provides information on the current supply with biological agents and its related costs in Germany. METHODS: A retrospective claims data analysis was conducted utilizing the Institute for Applied Health Research (InGef) Berlin, formerly HRI Health Risk Institute, database including approximately 6.7 million insured anonymities originating from 63 statutory health insurances in Germany. Analyses were performed by the InGef institute. A sample with approximately 4 million insured persons was drawn and stratified by age and gender according to the official demographic structure of the German statutory health insured population (DeStatis, Dec 31^st, 2013). Patient data from 2012 - 2016 were included if they met the following conditions: Main diagnosis of PsA (ICD-10 code L40.5), and start / maintenance / switch of treatment with PsA approved biological agent(s) (at least for three months). The study evaluated hospitalization, change in medication and direct medical costs (drug, outpatient care, hospitalization). RESULTS: The level of share of prescriptions of all biological agents considered is low. Adalimumab and etanercept are administered mostly to patients already on treatment (in 2015 adalimumab 38.3 % vs. etanercept 31.3 %). Total costs of the included 1’545 patients add up to € 27’612’238 in 2015. The total number of patients, the number of hospitalizations and the total treatment costs including three out of four cost items grew yearly on average between 9.8 % and 13.1 % (2012 – 2015). The costs of other medication dropped yearly on average by 2.8 %. Average hospitalization per patient remained constant (0.6). CONCLUSIONS: Adalimumab and etanercept are those biological agents mainly used by patients already on treatment. Costs grew steadily over the last 4 years. Total costs in 2015 were € 27.6 million (on average € 17’872 per patient).